Mode
Text Size
Log in / Sign up

Critically ill lung cancer patients face 73.5% long-term mortality and 51.9% hospital mortalityData shows lung cancer patients face high long-term mortality rates

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that critically ill lung cancer patients have poor long-term outcomes (73.5%) and require early goals of care discussions.

This meta-analysis evaluates the clinical outcomes and mortality predictors for patients with lung cancer in intensive care settings. The analysis synthesized data from large cohorts, including 16,772 patients for ICU mortality, 72,215 for hospital mortality, and 84,008 for long-term mortality.

Key findings indicate a 46.4% ICU mortality rate (95% CI 41.0-51.8) and a 51.9% hospital mortality rate (95% CI 46.9-56.9). Long-term mortality at 6-12 months was reported at 73.5% (95% CI 68.2-78.2). Several factors were identified as predictors of mortality, including metastatic disease (RR 1.30), poor performance status (RR 1.33), requirement for mechanical ventilation (RR 2.25), and requirement for vasopressors (RR 1.95). Additionally, higher APACHE or SAPS scores (SMD 0.63) and higher SOFA scores (MD 1.95) were associated with increased mortality.

Clinicians should note that while short-term outcomes are described as reasonable, long-term outcomes are poor for this population. These findings suggest that early and focused goals of care discussions are a critical component of ICU management for patients with lung cancer.

How this fits prior evidence

This meta-analysis addresses a gap in understanding the specific prognosis of critically ill patients with lung cancer. While previous evidence noted that statin use is associated with improved overall survival and progression-free survival in lung cancer patients treated with immune checkpoint inhibitors, this study focuses on the acute and sub-acute mortality of those in intensive care. It confirms that long-term outcomes for this specific subset remain poor, regardless of the specific treatments mentioned in prior coverage.

When a patient with lung cancer ends up in the intensive care unit, the medical team faces a complex challenge. They must balance immediate life-saving treatments with the reality of the patient's long-term outlook. New data looking at over 84,000 patients shows that while some survive the initial hospital stay, the long-term survival rate remains low, with 73.5% of patients passing away within 6 to 12 months.

The study looked at thousands of patients to identify what factors predict these outcomes. Factors like needing a breathing machine (mechanical ventilation) or medicine to support blood pressure (vasopressors) were linked to higher risks. Other factors included having metastatic disease, which means the cancer has spread, or a poor performance status before entering the hospital.

Because of these findings, experts suggest that early and focused conversations about goals of care are vital. These talks help families and doctors decide on the best path forward during the critical time a patient spends in the intensive care unit.

What this means for you:
Lung cancer patients in intensive care face high long-term mortality, making early goals of care discussions vital.

Common questions

What are the survival rates for lung cancer patients in intensive care?

The data shows that 46.4% of patients with lung cancer in the intensive care unit died. For those who survived the initial period, the hospital mortality rate was 51.9%. However, the long-term mortality rate was much higher, with 73.5% of patients passing away within 6 to 12 months of their stay.

What factors make the outlook harder for these patients?

Several factors were linked to a higher risk of death. These include having metastatic disease (cancer that has spread), a poor performance status, and the need for mechanical ventilation or vasopressors (medication to support blood pressure). Higher scores on medical scales like APACHE, SAPS, and SOFA also predicted worse outcomes.

How should doctors and families handle these cases?

Because lung cancer patients in intensive care have poor long-term outcomes, experts say that focused and early goals of care discussions are a crucial part of treatment. These conversations help ensure that the care provided in the intensive care unit aligns with the patient's wishes and goals.

Study Details

Study typeMeta analysis
EvidenceLevel 1
Follow-up12.0 mo
PublishedSep 2026
View Original Abstract ↓
IntroductionDespite recent advances in the care of critically ill patients with cancer, studies show that lung cancer is associated with higher Intensive Care Unit (ICU) mortality than other types of cancer. This systematic review and meta-analysis aim to investigate the ICU outcomes and predictors of mortality in critically ill patients with lung cancer.MethodsPubMed, OVID MEDLINE, Cochrane and Embase were searched to identify relevant studies. The primary outcome was ICU mortality. The secondary outcomes were hospital mortality and predictors of mortality. Abstracts, case reports and case series were excluded.ResultsThirty-three studies met inclusion criteria, including 28 cohort studies (n = 4123) and five population-based studies (n = 82,475). The pooled ICU mortality was 46.4% (95% CI 41.0-51.8; n = 16,772). The pooled hospital mortality was 51.9% (95% CI 46.9-56.9; n = 72,215). The pooled long-term mortality (6-12 months) was 73.5%, (95% CI 68.2- 78.2; n = 84,008). Predictors of mortality included the presence of metastatic disease (RR 1.30, 95% CI 1.06-1.59), poor performance status (RR 1.33, 95% CI 1.12-1.57), requirement for mechanical ventilation (RR 2.25, 95% CI 1.58-3.21), requirement for vasopressors (RR 1.95, 95% CI 1.54-2.46), higher APACHE or SAPS score (standardized mean difference 0.63, 95% CI 0.45-0.80), and higher SOFA score (mean difference 1.95, 95% CI 1.21-2.70).ConclusionCritically ill patients with lung cancer have reasonable short term but poor long-term outcome. Focused and early goals of care discussions are crucial part of ICU care in this patient population.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.